» Articles » PMID: 25822415

CRISPathBrick: Modular Combinatorial Assembly of Type II-A CRISPR Arrays for DCas9-Mediated Multiplex Transcriptional Repression in E. Coli

Overview
Journal ACS Synth Biol
Date 2015 Mar 31
PMID 25822415
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Programmable control over an addressable global regulator would enable simultaneous repression of multiple genes and would have tremendous impact on the field of synthetic biology. It has recently been established that CRISPR/Cas systems can be engineered to repress gene transcription at nearly any desired location in a sequence-specific manner, but there remain only a handful of applications described to date. In this work, we report development of a vector possessing a CRISPathBrick feature, enabling rapid modular assembly of natural type II-A CRISPR arrays capable of simultaneously repressing multiple target genes in Escherichia coli. Iterative incorporation of spacers into this CRISPathBrick feature facilitates the combinatorial construction of arrays, from a small number of DNA parts, which can be utilized to generate a suite of complex phenotypes corresponding to an encoded genetic program. We show that CRISPathBrick can be used to tune expression of plasmid-based genes and repress chromosomal targets in probiotic, virulent, and commonly engineered E. coli strains. Furthermore, we describe development of pCRISPReporter, a fluorescent reporter plasmid utilized to quantify dCas9-mediated repression from endogenous promoters. Finally, we demonstrate that dCas9-mediated repression can be harnessed to assess the effect of downregulating both novel and computationally predicted metabolic engineering targets, improving the yield of a heterologous phytochemical through repression of endogenous genes. These tools provide a platform for rapid evaluation of multiplex metabolic engineering interventions.

Citing Articles

Enhanced biosynthesis of poly(3-hydroxybutyrate) in engineered strains of Pseudomonas putida via increased malonyl-CoA availability.

Favoino G, Krink N, Schwanemann T, Wierckx N, Nikel P Microb Biotechnol. 2024; 17(11):e70044.

PMID: 39503721 PMC: 11539682. DOI: 10.1111/1751-7915.70044.


Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.

Sultana R, Kamihira M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459002 PMC: 11510354. DOI: 10.3390/ph17101362.


CRISPRpi: Inducing and Curing Prophage Using the CRISPR Interference.

Cornuault J Methods Mol Biol. 2024; 2793:257-271.

PMID: 38526735 DOI: 10.1007/978-1-0716-3798-2_16.


A randomized multiplex CRISPRi-Seq approach for the identification of critical combinations of genes.

Ellis N, Myers K, Tung J, Davidson Ward A, Johnston K, Bonnington K Elife. 2023; 12.

PMID: 38095310 PMC: 10721215. DOI: 10.7554/eLife.86903.


AspFlex: Molecular Tools to Study Gene Expression and Regulation in .

Brychcy M, Kokodynski A, Lloyd D, Godoy V ACS Synth Biol. 2023; 12(9):2773-2777.

PMID: 37587063 PMC: 10621034. DOI: 10.1021/acssynbio.3c00167.